Expanding globally with new partnerships but facing rising regulatory risks
- The company reported $126.0 million of net income in 2024, proving its original subscription model can scale profitably.
- The $1.15 billion acquisition of Eucalyptus expanded operations globally, giving the company three overseas markets pacing above a $100 million run rate.
- A new partnership with Lilly adds Zepbound and Mounjaro to the platform, preparing the company for a massive early 2027 weight loss rollout.
- Management intentionally pulled back marketing in the third quarter of 2026, causing a 100,000 sequential subscriber decline.
- The Federal Trade Commission filed a formal complaint against the company in July 2026, elevating regulatory risks.
A global shift beyond the shortage
Hims & Hers proved that its telehealth model could scale profitably in 2024. But the story shifted dramatically in early 2025 when the FDA resolved the semaglutide shortage. That event limited the company's ability to sell mass compounded weight loss drugs, forcing management to adapt quickly.
The bull case focuses on exceptional operational execution and AI driven operating leverage. Hims transitioned its weight loss users to 503A compounding based on clinical necessity and secured a direct supply of branded GLP-1 options from Novo Nordisk and Lilly. At the same time, the company aggressively expanded internationally, completing a $1.15 billion acquisition of Eucalyptus. The international segment is now pacing toward a $1 billion annual revenue run rate in 2027.
The bear case centers on execution, margin, and regulatory risks. A deliberate marketing pullback in the third quarter of 2026 resulted in a 100,000 sequential subscriber decline, highlighting a heavy reliance on customer acquisition spending. The FTC has officially filed a complaint against the company, presenting near-term litigation costs. Furthermore, moving weight loss users from high margin compounded products to branded options could pressure earnings.
Subscriptions, personalization, and vertical integration
Hims & Hers generates revenue by connecting patients with licensed healthcare providers online and selling them prescription or wellness products. Most customers sign up for recurring deliveries, making subscription behavior central to the model. The company protects its market share through brand recognition and a scalable customer acquisition engine.
The business is evolving to control more of the value chain. Hims now operates FDA registered compounding facilities, a peptide manufacturing site, and an integrated lab testing business. By controlling the supply chain, the company aims to offer personalized solutions that standard pharmacies cannot match. Artificial intelligence initiatives are driving tangible operational leverage, handling routine work for 70 percent of weight loss subscribers and reducing support tasks materially.
The model breaks if customer acquisition costs spike, if churn rises, or if regulators limit key products. With the pivot to global markets, the company now faces the added complexity of managing direct-to-consumer health regulations in multiple foreign jurisdictions.
From reactive conditions to proactive care
Weight loss
This specialty includes compounded options, generic liraglutide, and branded Wegovy and Zepbound. It drives massive growth but faces ongoing regulatory and margin scrutiny.
Hormone therapy and lab testing
A push into proactive care featuring testosterone replacement therapy and comprehensive blood testing, designed to increase long term subscriber loyalty.
Peptides Plus
Hims is launching new options like sermorelin and glutathione, while validating active pharmaceutical ingredients in its Menlo Park facility.
Sexual health
One of the original categories. It anchors the brand with reliable subscription revenue from treatments customers prefer to buy privately.
Dermatology and hair loss
These products fit the recurring delivery model perfectly. Personalized formulas help keep users engaged month after month.
Mental health
Digital access to mental health care adds breadth to the platform, though it must operate within strict prescribing rules.
A new geographic split
Mix reflects the updated reporting structure introduced in Q1 2026 following major international acquisitions. The company now reports United States Revenue and Rest of the World Revenue instead of Online and Wholesale.
What could break the story
FTC litigation and regulatory scrutiny
High impact · High oddsThe Federal Trade Commission filed a formal complaint against the company on July 29, 2026. This escalation from a non-public investigation introduces near-term litigation costs and potential long-term operational remedies.
Customer acquisition dependency
High impact · Medium oddsThe company lost 100,000 net subscribers sequentially in the third quarter of 2026 after intentionally pulling back marketing spend. This highlights the business model's heavy reliance on continuous ad spending to maintain growth.
Lower margin weight loss mix
High impact · Medium oddsMoving users from compounded semaglutide to branded Wegovy or Zepbound keeps them on the platform, but these branded drugs typically carry lower margins. If alternatives cost more to source, earnings quality could weaken.
Integration of global acquisitions
High impact · Medium oddsThe company spent $1.15 billion on Eucalyptus and bought other international brands. Integrating these operations across multiple countries brings massive execution risk and exposure to different health regulations.
In one breath
How does Hims & Hers make money?
The company generates revenue primarily by selling prescription treatments, personalized health products, and lab testing through a recurring subscription model on its digital platform.
Why did the company change its business segments?
Following the $1.15 billion acquisition of Eucalyptus and other international brands, Hims restructured its reporting to focus on United States Revenue versus Rest of the World Revenue.
How did the FDA semaglutide shortage impact the stock?
Compounded semaglutide drove massive weight loss growth. The FDA resolved the shortage in February 2025, forcing Hims to pivot to 503A compounding and direct partnerships for branded GLP-1 drugs.
Is Hims & Hers profitable?
Yes. The company reached its first full year of profitability on a net income basis in 2024, reporting $126.0 million in net income.
Sources and research notes
This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.
- Thesis reviewed
- November 15, 2026
- Score data
- November 15, 2026
- Reviewed by
- Shivam Bharuka
Comparable Household & Personal Products companies
Companies near Hims & Hers Health, Inc. in Finn's Household & Personal Products industry ranking.

